The tower sale will help bring down debt
Approval to Teva for key drug Lialda and sustained price erosion lead to stock downgrades
Rising raw material costs can weigh on margins in coming quarters
Robust growth in the non-life segment, diversified book and improving operational efficiencies are positives
Analysts expect policies by the new management will sustain same-store sales growth, while prudence in store expansion will help control costs
Recovery led by new launches at JLR, revised hedging policy, and margin gains
Pricing pressure is negating upsides from new products
Land sales and improvement in return ratios would lead to re-rating
Sorting out regulatory issues would lead to a re-rating
Share of auto segments, complete systems offerings to help margins
10% cess hike will impact auto major most, given its large exposure to the utility vehicles segment
Market share gains, profitable regional expansion bode well for volumes and yields
Healthy outlook on strong margins, niche product launches and traction in key regulatory markets
A muted revenue outlook and higher costs will keep margins and earnings under pressure in FY18
Change in operating model and issues related to the Airbus A320neo will be key triggers
Demand shift to current quarter on account of GST, good monsoon are triggers
Traction in new services a big trigger; gains on operational front depend on keeping costs control
Growth rate and margin could see downward trend in near term
Agri loan waiver, good monsoon and GST will help it grow at a faster pace
Cost and reach benefits from merger with Videocon d2h only trigger